The phone rang at 3:47 PM on a Tuesday.
Sarah , CFO of a mid-sized biotech firm in San Diego, glanced at the caller ID. It was her CEO, Marcus. She picked up immediately.
“Sarah, it’s Marcus.” The voice was unmistakable, the slight rasp, the Boston accent that crept in when he was stressed, even the way he paused before getting to the point. “Listen, I’m in a meeting with the acquisition team. We need to wire $340,000 to secure the due diligence escrow by end of day. I’m sending you the account details now.”